Targeting the weaknesses of aggressive breast cancer cells
Targeting Metabolic Vulnerabilities of Triple Negative Breast Cancer Stem Cells
This study is looking for new ways to treat triple negative breast cancer by testing a special compound that might help kill the stubborn cancer stem cells, and it will also see how this treatment works with the immune system to fight the cancer better.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Michigan at Ann Arbor NIH-funded |
| Lab location | 1 site (Ann Arbor, United States) |
| Project ID | NIH-10977363 on NIH RePORTER |
What this research studies
This research focuses on triple negative breast cancer (TNBC), which is known for its aggressive nature and limited treatment options. The study aims to identify new therapies that specifically target cancer stem-like cells (CSCs) in TNBC, which are believed to contribute to poor patient outcomes. By using a compound called IB-DNQ that generates reactive oxygen species, the researchers will explore its effectiveness in killing these CSCs, both alone and in combination with another treatment that inhibits a specific enzyme. The research will also investigate how this approach affects the immune response against the tumor.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with triple negative breast cancer who have limited treatment options.
Not a fit: Patients with other subtypes of breast cancer or those who do not have cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients with triple negative breast cancer, potentially improving survival rates and reducing recurrence.
How similar studies have performed: Other research has shown promise in targeting cancer stem cells with similar approaches, indicating potential for success in this novel strategy.
Where this research is happening
Ann Arbor, United States
- University of Michigan at Ann Arbor — Ann Arbor, United States (Active)
Researchers
- Principal investigator: Wicha, Max S. — University of Michigan at Ann Arbor
- Study coordinator: Wicha, Max S.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.